Log in

NASDAQ:VKTXViking Therapeutics Stock Price, Forecast & News

$6.85
+0.14 (+2.09 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.51
Now: $6.85
$6.86
50-Day Range
$6.66
MA: $7.27
$8.08
52-Week Range
$3.26
Now: $6.85
$8.87
Volume1.13 million shs
Average Volume1.50 million shs
Market Capitalization$497.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
Viking Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.83 per share

Profitability

Net Income$-25,780,000.00

Miscellaneous

Employees17
Market Cap$497.28 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

How has Viking Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VKTX shares have increased by 35.1% and is now trading at $6.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Viking Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viking Therapeutics.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Viking Therapeutics.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) posted its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. View Viking Therapeutics' earnings history.

What price target have analysts set for VKTX?

13 brokerages have issued twelve-month price objectives for Viking Therapeutics' stock. Their forecasts range from $9.00 to $25.00. On average, they expect Viking Therapeutics' share price to reach $14.50 in the next year. This suggests a possible upside of 111.7% from the stock's current price. View analysts' price targets for Viking Therapeutics.

Has Viking Therapeutics been receiving favorable news coverage?

Media stories about VKTX stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viking Therapeutics earned a news impact score of -4.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the next few days. View the latest news about Viking Therapeutics.

Are investors shorting Viking Therapeutics?

Viking Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 11,210,000 shares, a decline of 8.5% from the May 31st total of 12,250,000 shares. Based on an average trading volume of 1,730,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 15.9% of the shares of the stock are sold short. View Viking Therapeutics' Current Options Chain.

Who are some of Viking Therapeutics' key competitors?

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), Micron Technology (MU), Crispr Therapeutics (CRSP) and SCYNEXIS (SCYX).

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 54, Pay $735k)
  • Mr. Gregory S. Zante, Sr. VP of Fin. (Age 49)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 55)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Exane Derivatives (0.06%) and Envestnet Asset Management Inc. (0.04%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr. View institutional ownership trends for Viking Therapeutics.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, and Envestnet Asset Management Inc.. View insider buying and selling activity for Viking Therapeutics.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.85.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $497.28 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.